**Question:** Gleason score is used to grade:

A. Tumor grading in prostate cancer
B. Liver function tests
C. Skin pigmentation disorders
D. Cardiac infarct size assessment

**Core Concept:**
Gleason score is a system used to grade prostate cancer, particularly adenocarcinoma. It is a crucial tool in determining the prognosis and guiding treatment decisions for patients with prostate cancer. The Gleason score is based on the analysis of tissue samples obtained during a prostate biopsy.

**Why the Correct Answer is Right:**
Gleason score is based on the pattern and grade of glandular and acinar architecture in prostate cancer tissue samples. It is named after Dr. pathologist Dr. D. Gleason, who first described this grading system in 1966. The score ranges from 2 to 5, with higher scores indicating more aggressive disease. Gleason scores are assigned based on the predominant pattern and grade within the tissue sample. For example, a Gleason score of 3+4 would indicate a pattern of 3 and a pattern of 4 in the tissue, resulting in a total score of 7.

**Why Each Wrong Option is Incorrect:**

A. Liver function tests (Gleason score is not used for assessing liver health but rather for prostate cancer grading).
B. Cardiac infarct size assessment (Gleason score is unrelated to infarct size or cardiac health, but rather prostate cancer grading).
C. Skin pigmentation disorders (Gleason score is a prostate cancer grading tool, not related to skin pigmentation).
D. Tumor grading in prostate cancer (Gleason score is used for prostate cancer grading, not assessing cardiac infarct size or other unrelated conditions).

**Clinical Pearl:**

Gleason score is a crucial component of prostate cancer staging and treatment planning. It provides information about the aggressiveness of the cancer and helps predict the likelihood of tumor progression and patient survival. A higher Gleason score is associated with poorer prognosis and increased chances of disease progression. Understanding and interpreting Gleason scores is essential for clinicians managing patients with prostate cancer.